Balanced news tone
News Sentiment
BIIB sentiment intelligence
Biogen Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
81/100 classification confidence.
directly relevant articles
high-authority source matches
-11.4% over one week, +4.5% over four weeks, trend active, and materially above fair value.
Biogen Shares Decline After Detailed Diranersen Alzheimer's Study Data
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Biogen Shares Decline After Detailed Diranersen Alzheimer's Study Data
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 15 Jul 2026 14:51
- Source
- Yahoo! Finance Canada
Biogen's incoming legal chief has 20 years in biotech leadership
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 12:15
- Source
- Stock Titan
AAIC26: Biogen stock drops after unveiling tau-targeting ASO data
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 10:38
- Source
- Clinical Trials Arena
Biogen (BIIB) Following Fresh Alzheimer’s Data Is The Upside Story Still Intact
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 15 Jul 2026 02:11
- Source
- Market source
Biogen Dips As Questions Weigh On Alzheimer's 'Breakthrough'
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 20:13
- Source
- Investor's Business Daily
Biogen’s Alzheimer’s Drug Leaves Questions Unanswered, and That’s a Problem
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 18:09
- Source
- Barron's
Biogen defends anti-tau drug after stock slides on Alzheimer’s readout
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 18:00
- Source
- Fierce Biotech
Biogen stock falls 8% on Alzheimer's drug diranersen trial data
- Tone
- Negative 22/100
- Event
- Market update
- Published
- 14 Jul 2026 17:42
- Source
- qz.com
Biogen slides as investors reassess Alzheimer’s data and earnings overhang
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 Jul 2026 14:51
- Source
- Quiver Quantitative
How Investors Are Reacting To Biogen (BIIB) At-Home LEQEMBI Autoinjector Approval
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 14 Jul 2026 14:14
- Source
- Market source
Biogen Shares Rise After Positive Phase 2 Alzheimer’s Trial Results (BIIB)
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 14 Jul 2026 13:48
- Source
- Market source
Biogen Stock Is Upgraded to Buy Ahead of Key Alzheimer’s Drug Study Details
- Tone
- Positive 84/100
- Event
- Analyst action
- Published
- 13 Jul 2026 18:32
- Source
- Barron's
Here is Why Biogen (BIIB) is One of the Most Undervalued NASDAQ Stocks to Buy Right Now
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 05 Jul 2026 07:00
- Source
- Market source
Biogen (BIIB) Moves 7.0% Higher: Will This Strength Last?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 29 Jun 2026 07:00
- Source
- Market source
Why Biogen (BIIB) Stock Is Up Today
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 07:00
- Source
- Market source
Biogen stock price forecast: $174.41 support comes into view as BIIB slips 1.94%
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 19 Jun 2026 07:00
- Source
- Traders Union
Biogen (BIIB) Stock Could Be 10.3% Undervalued on Its Pipeline Narrative
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 07:00
- Source
- Market source
Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 17 Jun 2026 07:00
- Source
- Biogen
Biogen Completes Acquisition of Apellis Pharmaceuticals
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 14 May 2026 07:00
- Source
- Biogen
Biogen to Participate in the Bank of America Securities 2026 Health Care Conference
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 May 2026 07:00
- Source
- Biogen
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
- Tone
- Positive 95/100
- Event
- Guidance
- Published
- 31 Mar 2026 07:00
- Source
- Biogen
Biogen Completes Acquisition of Alcyone Therapeutics
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 14 Nov 2025 08:00
- Source
- Biogen
Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 23 Sep 2025 07:00
- Source
- Biogen
Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Aug 2025 07:00
- Source
- Biogen
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Feb 2025 08:00
- Source
- Biogen
Biogen Completes Acquisition of Reata Pharmaceuticals
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 26 Sep 2023 07:00
- Source
- Biogen
Biogen to Acquire Reata Pharmaceuticals
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jul 2023 07:00
- Source
- Biogen
Biogen Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental Biologics License Application for the Potential Traditional Approval of LEQEMBI in Early Alzheimer’s Disease
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 09 Jun 2023 07:00
- Source
- Biogen
Biogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for up to $2.3 billion
- Tone
- Negative 34/100
- Event
- Deals and strategy
- Published
- 27 Jan 2022 08:00
- Source
- Biogen
Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Nov 2020 08:00
- Source
- Biogen